Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aqua Pharmaceuticals, LLC Appoints Ted White as COO, Mark Boyer as Director of Finance

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
White moves to the new role from his previous position as Vice President of Sales, while Boyer advances from his former position as Controller.

As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-command to the company’s President and CEO, Craig Ballaron.

“I can always depend on Ted to be ahead of the curve,” said Ballaron. “He’s a fantastic manager, and his combination of sales savvy and steadfast leadership have helped him move up quickly within the company.”

White joined Aqua in 2011 following a successful 21-year sales career with Novartis Pharmaceutical Corporation, where he led sales teams in new product launches and executed tactics for multiple billion-dollar brands. In July 2010, PharmaVoice magazine named him one of the top 100 inspirational leaders in the health sciences field.

As the new Director of Finance, Boyer, who is a licensed CPA, will manage the company’s budget and lay out operational fiscal policies.

“Having someone with a solid, analytical understanding of both numbers and the pharmaceutical industry in general is invaluable to Aqua,” said Ballaron. “As Controller, Mark demonstrated a knack for both. He’s adept at data analysis and managing corporate funds, so moving to the role of Director of Finance was a natural progression.”

Prior to joining Aqua in 2010, Boyer worked as a Senior Accountant for Teleflex Incorporated’s ARROW International division, where he was responsible for financial reporting, Sarbanes-Oxley compliance and fixed-asset management.

“This is a dynamic time of growth and change for Aqua,” said Ballaron. “I am excited to help write the next phase in our company’s history with Ted and Mark at my side.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!